Total adverse events · Adults with acute asthma
Combination inhaled therapy probably leads to higher total adverse events compared with SABA alone (moderate certainty).
1 finding from 1 review
FEV1 · Adults with acute asthma
1 finding from 1 review
Percent change FEV₁(%) · Adults with acute asthma
1 finding from 1 review
Health outcomes Peak expiratory flow readings (higher readings indicate better peak flow) · Adults with acute asthma
1 finding from 1 review
Change in PEF · Adults with acute asthma
1 finding from 1 review
Relapse · Adults with acute asthma
Combination inhaled therapy probably leads to lower relapse rates compared with SABA alone (moderate certainty).
1 finding from 1 review
Primary outcome · adults with subacute and chronic cough
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who achieved clinical cure or significant improvement (> 70% reduction in cough severity measure) at · adults with subacute and chronic cough
1 finding from 1 review
Secondary outcomes · adults with subacute and chronic cough
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who achieved clinical cure or > 50% reduction in cough severity measure at · adults with subacute and chronic cough
1 finding from 1 review
Clinical cure · adults with subacute and chronic cough
1 finding from 1 review
Severity of cough (mean improvement score) · adults with subacute and chronic cough
Inhaled corticosteroids (ICS) showed no clear difference in mean change in cough score Symptomatic cough severity measure as… compared with placebo (low certainty).
1 finding from 1 review
Proportion with adverse effects of treatment · adults with subacute and chronic cough
Inhaled corticosteroids (ICS) showed no clear difference in proportion with adverse effects of treatment compared with placebo (moderate certainty).
1 finding from 1 review
CLD at 36 weeks' PMA · very low birth weight preterm neonates
Early inhaled steroid (< 2 weeks) probably leads to lower CLD at 36 weeks' PMA compared with placebo (among survivors) (moderate certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · very low birth weight preterm neonates
Early inhaled steroids (< 2 weeks) showed no clear difference in CLD at 36 weeks' PMA oxygen dependency at 36 weeks' PMA compared with placebo (among all randomised) (moderate certainty).
1 finding from 1 review
Death by, or CLD at, 36 weeks' PMA Death or oxygen dependency at 36 weeks' PMA · very low birth weight preterm neonates
Early inhaled steroids (< 2 weeks) probably leads to lower death by, or CLD at, 36 weeks' PMA Death or oxygen dependency at 36… compared with placebo (among all randomised) (moderate certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).
1 finding from 1 review
Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of exacerbations(as reported by number of hospitalisations and number of courses and days on antibiotics) · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes number of exacerbations(as reported by number of hospitalisations… compared with placebo (very low certainty).
1 finding from 1 review
Participant‐reported symptom score: cough, wheeze and exercise tolerance · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes participant‐reported symptom score: cough, wheeze and exercise… compared with placebo (very low certainty).
1 finding from 1 review